Suchergebnisse - "Fisher, Terrence L"

PubPharm (26)

1

Publisher Correction : Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial

enthalten in: Nature medicine | 2024

von Feigin, A. | Evans, E. | Fisher, T. | +49

ErratumFor: Nat Med. 2022 Oct;28(10):2183-2193. - PMID 35941373

2

SEMA4D blocking antibody, pepinemab, is a novel potential treatment for neurodegenerative disease : Clinical proof of concept in Phase 2 HD study supports ongoing clinical development in Phase 1/2 AD study

enthalten in: Alzheimer's & Dementia | 2023

von Fisher, T. | Evans, E. | Boise, M. | +12

3

Pepinemab antibody blockade of SEMA4D in early Huntington's disease : a randomized, placebo-controlled, phase 2 trial

enthalten in: Nature medicine | 2022

von Feigin, A. | Evans, E. | Fisher, T. | +49

ErratumIn: Nat Med. 2022 Oct 4;:. - PMID 36195687

4

Semaphorin 4D is upregulated in neurons of diseased brains and triggers astrocyte reactivity

enthalten in: Journal of neuroinflammation | 2022

von Evans, E. | Mishra, V. | Mallow, C. | +7

5

Semaphorin 4D is upregulated in neurons of diseased brains and triggers astrocyte reactivity

enthalten in: Journal of neuroinflammation | 2022

von Evans, E. | Mishra, V. | Mallow, C. | +7

6

Semaphorin 4D is upregulated in neurons of diseased brains and triggers astrocyte reactivity

enthalten in: Journal of neuroinflammation | 2022

von Evans, E. | Mishra, V. | Mallow, C. | +7

7

A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2021

von Shafique, M. | Fisher, T. | Evans, E. | +18

8

SEMA4D upregulation signals neuronal stress and triggers reactive transformation of astrocytes

enthalten in: ResearchSquare.com | 2021

von Zauderer, M. | Mishra, V. | Mallow, C. | +9

9

Evidence that semaphorin 4D is upregulated in neurons in Huntington’s and Alzheimer’s diseases : Effects of a SEMA4D blocking antibody on FDG‐PET in a clinical trial, and treatment rationale for its use in AD

enthalten in: Alzheimer's & Dementia | 2020

von Evans, E. | Fisher, T. | Leonard, J. | +9

10

Methods of treating multiple sclerosis using anti-CD20 antibodies

enthalten in: Europäisches Patentamt | 2019

von SMITH ERNEST S | FISHER TERRENCE L